Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

This study has been completed.
Sponsor:
Collaborator:
Nissho Nipro Europe
Information provided by:
University Hospital, Ghent
ClinicalTrials.gov Identifier:
NCT00230906
First received: September 29, 2005
Last updated: December 19, 2007
Last verified: December 2007
  Purpose

Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane


Condition Intervention
Haemodialysis
Procedure: Haemodialysis with either low or high flux membranes

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

Resource links provided by NLM:


Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • Concentration of uremic components after 3 weeks of haemodialysis

Estimated Enrollment: 12
Study Start Date: January 2001
Study Completion Date: April 2002
Detailed Description:

Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic haemodialysis patient
  • Serum albumin > 3.6 g/dl

Exclusion Criteria:

  • < 18 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00230906

Locations
Belgium
University Hospital Ghent
Ghent, Belgium, 9000
Sponsors and Collaborators
University Hospital, Ghent
Nissho Nipro Europe
Investigators
Principal Investigator: Raymond Van Holder, MD, PhD University Hospital, Ghent
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00230906     History of Changes
Other Study ID Numbers: 2001/182
Study First Received: September 29, 2005
Last Updated: December 19, 2007
Health Authority: Belgium: Institutional Review Board

ClinicalTrials.gov processed this record on September 30, 2014